The First FDA-Approved Pregabalin for Dogs Is Also a Test of the Conditional Pathway

A drug that's been prescribed off-label in veterinary medicine for over a decade just became the first canine pregabalin to clear FDA review — and it did so on the conditional pathway that has quietly become the most active regulatory track in animal health. Pegasus Laboratories' Liavium-CA1 received FDA conditional approval on May 18 for Chiari-like malformation and syringomyelia, a chronic neurologic pain condition most common in Cavalier King Charles Spaniels. The approval matters less for the indication than for what it signals about how specialty pet pharma now reaches market.

Pegasus secures FDA conditional approval for first canine pregabalin

Pegasus Laboratories, operating under its PRN Pharmacal brand, announced on May 18, 2026 that the FDA's Center for Veterinary Medicine granted conditional approval to Liavium-CA1 (pregabalin chewable tablets) under application 141-606. The product is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia (CM/SM) in dogs.

Pregabalin is a well-established human gabapentinoid sold under the brand Lyrica before generic entry. In veterinary medicine, it has been used off-label for years for canine neuropathic pain — including CM/SM, post-surgical neuropathy, and certain seizure-adjacent indications — but no labeled, FDA-overseen canine formulation existed until this approval.

The product will be available in 30 mg, 90 mg (scored for splitting), and 180 mg beef-flavored chewable tablets, dosed for dogs weighing approximately 6.6 to 50 pounds. As a Schedule V controlled substance, Liavium-CA1 carries the same dispensing, prescribing, and record-keeping requirements as human pregabalin. Prescription-only.

CM/SM is a hereditary structural condition of the cranio-cervical junction. The most affected breed by a wide margin is the Cavalier King Charles Spaniel, currently the AKC's 13th most popular breed. Published research puts Chiari-like malformation prevalence in adult Cavaliers as high as 95%, with syringomyelia (the symptomatic neurologic complication) reported at 39 to 46% in the breed overall. The share that becomes clinically symptomatic is substantially lower — cross-sectional estimates have placed symptomatic SM around 15%, with questionnaire-based estimates running as low as 3% and clinical-signs surveys ranging up to 35% depending on methodology. Hallmark signs include phantom scratching, vocalization, and head-and-neck sensitivity, all of which are routinely misdiagnosed as behavioral problems or simple aging. Many affected dogs remain untreated for years.

The conditional approval pathway, formally Expanded Conditional Approval (XCA) under the Animal Drug Availability Act, allows sponsors to market a drug for a serious or life-threatening condition or unmet need based on a reasonable expectation of effectiveness while continuing to gather full efficacy data. The clinical basis for Liavium-CA1's approval was a pilot study; Pegasus is now running a pivotal trial across U.S. investigator sites to support a transition to full approval.

Liavium-CA1 was originally developed by TriviumVet, an Ireland-based specialty veterinary pharmaceutical company. Pegasus acquired TriviumVet in 2025. The TriviumVet pipeline also includes felimazole and feline-medicine candidates, several of which are positioned for the same conditional pathway.

Why the pathway story is bigger than the indication

The CM/SM indication is meaningful but narrow. The Cavalier King Charles Spaniel population in the U.S. is small. The broader off-label canine neuropathic pain market is larger, but Liavium-CA1's label does not cover it directly. What makes this approval matter at scale is the regulatory machinery that produced it.

Three things are true about the FDA conditional pathway in 2026 that were not true three years ago.

1. Conditional approval is now the de facto launch path for specialty animal therapeutics. Loyal's LOY-002 (canine lifespan extension) is on the XCA path. KindredBio products were. Pegasus's KBroVet (potassium bromide for canine epilepsy) cleared full approval after an initial conditional approval and is now the first FDA fully approved pharmaceutical for that indication. Every specialty veterinary pharma company with a credible pipeline is now structuring trials specifically for conditional pathway eligibility. The full-approval path is reserved for major-pharma biologics and high-volume parasiticides.

2. The pathway compresses time-to-market by years for unmet-need indications. Liavium-CA1's full-approval pivotal trial is ongoing while the product reaches market. Pegasus monetizes the conditional period (up to five years, renewable) while completing the dataset for unconditional approval. For specialty veterinary companies funded by mid-size sponsors or PE-backed platforms, that revenue-during-trial economics is the difference between a viable business and a long-dated R&D bet.

3. The pathway has produced a small but real cluster of veterinary specialty buyouts. Pegasus acquiring TriviumVet in 2025 fits a pattern that includes Boehringer Ingelheim's specialty-asset accumulation, Elanco's bolt-ons through 2024-2025, and the early-stage backing of platforms like Loyal. Conditional-pathway-eligible assets are now an identifiable acquisition category.

For Pegasus specifically, Liavium-CA1 is the second high-visibility FDA-approved product in 18 months, after KBroVet's full approval. The company has executed a credible build under PBI-Gordon Companies ownership, moving from a contract manufacturing organization to a specialty-pharma platform with its own approved products. The TriviumVet acquisition adds a feline pipeline that should produce another launch within the next two years.

For veterinary specialists — particularly neurologists and behaviorists — Liavium-CA1 changes the prescribing economics on a chronic case load they have been managing with human pregabalin compounded for animal use. A labeled, palatable, FDA-overseen formulation removes compounding-quality concerns, gives owners a beef-flavored tablet rather than an off-label human capsule, and shifts the clinical liability picture. Prescribing volume should follow.

The harder question is general-practice penetration. CM/SM diagnosis requires MRI, which most general practices do not have. Awareness campaigns, breeder education, and screening protocols all need to step up before the indicated population is identified at scale. Pegasus has not disclosed revenue projections, but the on-label market is constrained by diagnosis rates rather than by the size of the affected population — the gap between the 39-46% of Cavaliers with SM and the much smaller share currently identified and treated is where commercial upside lives. Pegasus's commercial execution on the diagnosis pathway, not the product, decides whether Liavium-CA1 settles in as a small specialty product or scales into a meaningful franchise.

The off-label question is also live. Pregabalin's pharmacology supports a wider neuropathic pain use case than the CM/SM label. Veterinarians can legally prescribe Liavium-CA1 off-label for other neuropathic pain conditions, the same way they prescribe human pregabalin today. If general practitioners shift their existing pregabalin prescribing to the labeled veterinary product, the actual revenue base could exceed the on-label market by a wide margin. Pegasus cannot promote that use, but practice economics will drive it.

What this signals for the broader pet therapeutics pipeline

The pivotal trial readout. Pegasus is running a multi-site pivotal trial to support full approval. Timing has not been disclosed. Watch the conditional-approval clock: XCA allows up to five years before full data must be submitted. Pegasus's pace and any interim data disclosures will signal both regulatory confidence and the size of the indicated population the company is actually identifying.

Off-label prescribing volume. Animal pharmacy distributors and veterinary specialty pharmacies will see the off-label expansion before public disclosure does. The most observable signal will be whether human-pregabalin compounding volumes for veterinary use start to decline as Liavium-CA1 takes share.

The next TriviumVet pipeline launch. Pegasus inherited TriviumVet's broader pipeline in the 2025 acquisition. The next conditional approval candidate from that pipeline — likely a feline indication — will reveal whether the deal economics work as a platform play or a single-asset acquisition.

Conditional-pathway policy. The XCA pathway runs under congressional authorization that requires periodic reauthorization. The volume of specialty veterinary launches now using the pathway has grown to the point that any regulatory or legislative friction would meaningfully compress the specialty-pet-pharma deal flow. Industry-level lobbying activity through 2026-2027 will reflect this.

Source: Pegasus/PRN Pharmacal announcement via PR Newswire